Loading…
Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy
Background Patients with advanced non-small cell lung cancer (NSCLC) seem to have disparity in prognosis. Accurate prediction of prognosis could be useful in the future to predict individual risk and to develop more aggressive or alternative treatment strategies. Purpose To evaluate the prognostic v...
Saved in:
Published in: | Acta radiologica (1987) 2011-07, Vol.52 (6), p.646-650 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c360t-dabeab35c77c79af0f2c47b42346c0f394a3a1fe43744e1906bd4e69f9d8b5703 |
---|---|
cites | cdi_FETCH-LOGICAL-c360t-dabeab35c77c79af0f2c47b42346c0f394a3a1fe43744e1906bd4e69f9d8b5703 |
container_end_page | 650 |
container_issue | 6 |
container_start_page | 646 |
container_title | Acta radiologica (1987) |
container_volume | 52 |
creator | Yan, Hongjiang Wang, Renben Zhao, Fen Zhu, Kunli Jiang, Shumei Zhao, Wei Feng, Rui |
description | Background
Patients with advanced non-small cell lung cancer (NSCLC) seem to have disparity in prognosis. Accurate prediction of prognosis could be useful in the future to predict individual risk and to develop more aggressive or alternative treatment strategies.
Purpose
To evaluate the prognostic value of metabolic tumor volume (MTV) measured by 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in patients with NSCLC.
Material and Methods
We retrospectively reviewed 120 patients with pathologically proven NSCLC (61 squamous cell carcinomas and 59 adenocarcinomas) who underwent pretreatment 18F-FDG PET. MTV and maximum standardized uptake value (SUVmax) for the primary tumors were measured by 18F-FDG PET. Pretreatment variables (age, sex, American Joint Committee on Cancer [AJCC] stage, histological type, SUVmax, and MTV) were analyzed to identify their correlation with two-year survival. To further evaluate and compare the predictive value of PET parameters, MTV, and SUVmax, time-dependent receiver-operating characteristic curve (ROC) analysis was used.
Results
In the univariate analysis, AJCC stage, histological type, MTV, and SUVmax of primary tumor were significant predictors of survival. On multivariate analysis, independent prognostic factors associated with decreased two-year survival were AJCC stage (hazard ratio [HR] 2.236, P = 0.003), histological type (HR 2.038, P = 0. 004), and MTV (HR 1.016, P = 0.001). SUVmax was not a significant factor (HR 0.96, P = 0.490). On time-dependent ROC analysis, MTV showed good predictive performance for two-year survival consistently better than SUVmax.
Conclusion
MTV, a volumetric parameter of 18F-FDG PET, is an important independent prognostic factor for survival and a better predictor of survival than SUVmax for the primary tumor in patients with advanced NSCLC. |
doi_str_mv | 10.1258/ar.2011.100462 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_874483565</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1258_ar.2011.100462</sage_id><sourcerecordid>874483565</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-dabeab35c77c79af0f2c47b42346c0f394a3a1fe43744e1906bd4e69f9d8b5703</originalsourceid><addsrcrecordid>eNp1kTuP1DAUhS0EYoeFlhK5QRQow3Vs51Gi1fKQFkGx1NGNczObVWIPfsxqfgT_GYcZoKKxC3_n-N5zGHspYCtK3bxDvy1BiK0AUFX5iG1EBVCA0vox20DZqEI0WlywZyHcA4iy1uIpuyiFhibrNuznF8KQPC1kI3cjj2lxnh_cnBbi_ZF_u77l0XE64JwwEt97t7MuTIFPlu8xTlkX-MMU7zgOB7SGBm6dLcKC88wN5WNOdsfN-uR59JRdhtX5N5X8bjI483hHHvfH5-zJiHOgF-f7kn3_cH179am4-frx89X7m8LICmIxYE_YS23q2tQtjjCWRtW9KqWqDIyyVShRjKRkrRSJFqp-UFS1Yzs0va5BXrI3J9-8zo9EIXbLFNZh0ZJLoWuyrpG60pncnkjjXQiexm7vpwX9sRPQrQ106Lu1ge7UQBa8OlunfqHhL_4n8gy8PgMY8uqjz8lM4R-nJFTQqMy9PXEBd9Tdu-RtjuR_3_4Cc5Od-g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>874483565</pqid></control><display><type>article</type><title>Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy</title><source>Sage Journals Online</source><creator>Yan, Hongjiang ; Wang, Renben ; Zhao, Fen ; Zhu, Kunli ; Jiang, Shumei ; Zhao, Wei ; Feng, Rui</creator><creatorcontrib>Yan, Hongjiang ; Wang, Renben ; Zhao, Fen ; Zhu, Kunli ; Jiang, Shumei ; Zhao, Wei ; Feng, Rui</creatorcontrib><description>Background
Patients with advanced non-small cell lung cancer (NSCLC) seem to have disparity in prognosis. Accurate prediction of prognosis could be useful in the future to predict individual risk and to develop more aggressive or alternative treatment strategies.
Purpose
To evaluate the prognostic value of metabolic tumor volume (MTV) measured by 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in patients with NSCLC.
Material and Methods
We retrospectively reviewed 120 patients with pathologically proven NSCLC (61 squamous cell carcinomas and 59 adenocarcinomas) who underwent pretreatment 18F-FDG PET. MTV and maximum standardized uptake value (SUVmax) for the primary tumors were measured by 18F-FDG PET. Pretreatment variables (age, sex, American Joint Committee on Cancer [AJCC] stage, histological type, SUVmax, and MTV) were analyzed to identify their correlation with two-year survival. To further evaluate and compare the predictive value of PET parameters, MTV, and SUVmax, time-dependent receiver-operating characteristic curve (ROC) analysis was used.
Results
In the univariate analysis, AJCC stage, histological type, MTV, and SUVmax of primary tumor were significant predictors of survival. On multivariate analysis, independent prognostic factors associated with decreased two-year survival were AJCC stage (hazard ratio [HR] 2.236, P = 0.003), histological type (HR 2.038, P = 0. 004), and MTV (HR 1.016, P = 0.001). SUVmax was not a significant factor (HR 0.96, P = 0.490). On time-dependent ROC analysis, MTV showed good predictive performance for two-year survival consistently better than SUVmax.
Conclusion
MTV, a volumetric parameter of 18F-FDG PET, is an important independent prognostic factor for survival and a better predictor of survival than SUVmax for the primary tumor in patients with advanced NSCLC.</description><identifier>ISSN: 0284-1851</identifier><identifier>EISSN: 1600-0455</identifier><identifier>DOI: 10.1258/ar.2011.100462</identifier><identifier>PMID: 21508201</identifier><identifier>CODEN: ACRAE3</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Area Under Curve ; Biological and medical sciences ; Carcinoma, Non-Small-Cell Lung - diagnostic imaging ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Non-Small-Cell Lung - therapy ; Female ; Fluorodeoxyglucose F18 ; Humans ; Image Interpretation, Computer-Assisted ; Lung Neoplasms - diagnostic imaging ; Lung Neoplasms - pathology ; Lung Neoplasms - therapy ; Male ; Medical sciences ; Neoplasm Staging ; Pneumology ; Positron-Emission Tomography - methods ; Prognosis ; Radiopharmaceuticals ; Retrospective Studies ; ROC Curve ; Survival Rate ; Tumor Burden ; Tumors of the respiratory system and mediastinum</subject><ispartof>Acta radiologica (1987), 2011-07, Vol.52 (6), p.646-650</ispartof><rights>2011 The Foundation Acta Radiologica</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-dabeab35c77c79af0f2c47b42346c0f394a3a1fe43744e1906bd4e69f9d8b5703</citedby><cites>FETCH-LOGICAL-c360t-dabeab35c77c79af0f2c47b42346c0f394a3a1fe43744e1906bd4e69f9d8b5703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,79364</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24306084$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21508201$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yan, Hongjiang</creatorcontrib><creatorcontrib>Wang, Renben</creatorcontrib><creatorcontrib>Zhao, Fen</creatorcontrib><creatorcontrib>Zhu, Kunli</creatorcontrib><creatorcontrib>Jiang, Shumei</creatorcontrib><creatorcontrib>Zhao, Wei</creatorcontrib><creatorcontrib>Feng, Rui</creatorcontrib><title>Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy</title><title>Acta radiologica (1987)</title><addtitle>Acta Radiol</addtitle><description>Background
Patients with advanced non-small cell lung cancer (NSCLC) seem to have disparity in prognosis. Accurate prediction of prognosis could be useful in the future to predict individual risk and to develop more aggressive or alternative treatment strategies.
Purpose
To evaluate the prognostic value of metabolic tumor volume (MTV) measured by 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in patients with NSCLC.
Material and Methods
We retrospectively reviewed 120 patients with pathologically proven NSCLC (61 squamous cell carcinomas and 59 adenocarcinomas) who underwent pretreatment 18F-FDG PET. MTV and maximum standardized uptake value (SUVmax) for the primary tumors were measured by 18F-FDG PET. Pretreatment variables (age, sex, American Joint Committee on Cancer [AJCC] stage, histological type, SUVmax, and MTV) were analyzed to identify their correlation with two-year survival. To further evaluate and compare the predictive value of PET parameters, MTV, and SUVmax, time-dependent receiver-operating characteristic curve (ROC) analysis was used.
Results
In the univariate analysis, AJCC stage, histological type, MTV, and SUVmax of primary tumor were significant predictors of survival. On multivariate analysis, independent prognostic factors associated with decreased two-year survival were AJCC stage (hazard ratio [HR] 2.236, P = 0.003), histological type (HR 2.038, P = 0. 004), and MTV (HR 1.016, P = 0.001). SUVmax was not a significant factor (HR 0.96, P = 0.490). On time-dependent ROC analysis, MTV showed good predictive performance for two-year survival consistently better than SUVmax.
Conclusion
MTV, a volumetric parameter of 18F-FDG PET, is an important independent prognostic factor for survival and a better predictor of survival than SUVmax for the primary tumor in patients with advanced NSCLC.</description><subject>Area Under Curve</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Non-Small-Cell Lung - diagnostic imaging</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - therapy</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Humans</subject><subject>Image Interpretation, Computer-Assisted</subject><subject>Lung Neoplasms - diagnostic imaging</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neoplasm Staging</subject><subject>Pneumology</subject><subject>Positron-Emission Tomography - methods</subject><subject>Prognosis</subject><subject>Radiopharmaceuticals</subject><subject>Retrospective Studies</subject><subject>ROC Curve</subject><subject>Survival Rate</subject><subject>Tumor Burden</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0284-1851</issn><issn>1600-0455</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp1kTuP1DAUhS0EYoeFlhK5QRQow3Vs51Gi1fKQFkGx1NGNczObVWIPfsxqfgT_GYcZoKKxC3_n-N5zGHspYCtK3bxDvy1BiK0AUFX5iG1EBVCA0vox20DZqEI0WlywZyHcA4iy1uIpuyiFhibrNuznF8KQPC1kI3cjj2lxnh_cnBbi_ZF_u77l0XE64JwwEt97t7MuTIFPlu8xTlkX-MMU7zgOB7SGBm6dLcKC88wN5WNOdsfN-uR59JRdhtX5N5X8bjI483hHHvfH5-zJiHOgF-f7kn3_cH179am4-frx89X7m8LICmIxYE_YS23q2tQtjjCWRtW9KqWqDIyyVShRjKRkrRSJFqp-UFS1Yzs0va5BXrI3J9-8zo9EIXbLFNZh0ZJLoWuyrpG60pncnkjjXQiexm7vpwX9sRPQrQ106Lu1ge7UQBa8OlunfqHhL_4n8gy8PgMY8uqjz8lM4R-nJFTQqMy9PXEBd9Tdu-RtjuR_3_4Cc5Od-g</recordid><startdate>20110701</startdate><enddate>20110701</enddate><creator>Yan, Hongjiang</creator><creator>Wang, Renben</creator><creator>Zhao, Fen</creator><creator>Zhu, Kunli</creator><creator>Jiang, Shumei</creator><creator>Zhao, Wei</creator><creator>Feng, Rui</creator><general>SAGE Publications</general><general>Royal Society of Medicine</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110701</creationdate><title>Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy</title><author>Yan, Hongjiang ; Wang, Renben ; Zhao, Fen ; Zhu, Kunli ; Jiang, Shumei ; Zhao, Wei ; Feng, Rui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-dabeab35c77c79af0f2c47b42346c0f394a3a1fe43744e1906bd4e69f9d8b5703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Area Under Curve</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Non-Small-Cell Lung - diagnostic imaging</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - therapy</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Humans</topic><topic>Image Interpretation, Computer-Assisted</topic><topic>Lung Neoplasms - diagnostic imaging</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neoplasm Staging</topic><topic>Pneumology</topic><topic>Positron-Emission Tomography - methods</topic><topic>Prognosis</topic><topic>Radiopharmaceuticals</topic><topic>Retrospective Studies</topic><topic>ROC Curve</topic><topic>Survival Rate</topic><topic>Tumor Burden</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yan, Hongjiang</creatorcontrib><creatorcontrib>Wang, Renben</creatorcontrib><creatorcontrib>Zhao, Fen</creatorcontrib><creatorcontrib>Zhu, Kunli</creatorcontrib><creatorcontrib>Jiang, Shumei</creatorcontrib><creatorcontrib>Zhao, Wei</creatorcontrib><creatorcontrib>Feng, Rui</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta radiologica (1987)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yan, Hongjiang</au><au>Wang, Renben</au><au>Zhao, Fen</au><au>Zhu, Kunli</au><au>Jiang, Shumei</au><au>Zhao, Wei</au><au>Feng, Rui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy</atitle><jtitle>Acta radiologica (1987)</jtitle><addtitle>Acta Radiol</addtitle><date>2011-07-01</date><risdate>2011</risdate><volume>52</volume><issue>6</issue><spage>646</spage><epage>650</epage><pages>646-650</pages><issn>0284-1851</issn><eissn>1600-0455</eissn><coden>ACRAE3</coden><abstract>Background
Patients with advanced non-small cell lung cancer (NSCLC) seem to have disparity in prognosis. Accurate prediction of prognosis could be useful in the future to predict individual risk and to develop more aggressive or alternative treatment strategies.
Purpose
To evaluate the prognostic value of metabolic tumor volume (MTV) measured by 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in patients with NSCLC.
Material and Methods
We retrospectively reviewed 120 patients with pathologically proven NSCLC (61 squamous cell carcinomas and 59 adenocarcinomas) who underwent pretreatment 18F-FDG PET. MTV and maximum standardized uptake value (SUVmax) for the primary tumors were measured by 18F-FDG PET. Pretreatment variables (age, sex, American Joint Committee on Cancer [AJCC] stage, histological type, SUVmax, and MTV) were analyzed to identify their correlation with two-year survival. To further evaluate and compare the predictive value of PET parameters, MTV, and SUVmax, time-dependent receiver-operating characteristic curve (ROC) analysis was used.
Results
In the univariate analysis, AJCC stage, histological type, MTV, and SUVmax of primary tumor were significant predictors of survival. On multivariate analysis, independent prognostic factors associated with decreased two-year survival were AJCC stage (hazard ratio [HR] 2.236, P = 0.003), histological type (HR 2.038, P = 0. 004), and MTV (HR 1.016, P = 0.001). SUVmax was not a significant factor (HR 0.96, P = 0.490). On time-dependent ROC analysis, MTV showed good predictive performance for two-year survival consistently better than SUVmax.
Conclusion
MTV, a volumetric parameter of 18F-FDG PET, is an important independent prognostic factor for survival and a better predictor of survival than SUVmax for the primary tumor in patients with advanced NSCLC.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>21508201</pmid><doi>10.1258/ar.2011.100462</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0284-1851 |
ispartof | Acta radiologica (1987), 2011-07, Vol.52 (6), p.646-650 |
issn | 0284-1851 1600-0455 |
language | eng |
recordid | cdi_proquest_miscellaneous_874483565 |
source | Sage Journals Online |
subjects | Area Under Curve Biological and medical sciences Carcinoma, Non-Small-Cell Lung - diagnostic imaging Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - therapy Female Fluorodeoxyglucose F18 Humans Image Interpretation, Computer-Assisted Lung Neoplasms - diagnostic imaging Lung Neoplasms - pathology Lung Neoplasms - therapy Male Medical sciences Neoplasm Staging Pneumology Positron-Emission Tomography - methods Prognosis Radiopharmaceuticals Retrospective Studies ROC Curve Survival Rate Tumor Burden Tumors of the respiratory system and mediastinum |
title | Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T01%3A11%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Measurement%20of%20tumor%20volume%20by%20PET%20to%20evaluate%20prognosis%20in%20patients%20with%20advanced%20non-small%20cell%20lung%20cancer%20treated%20by%20non-surgical%20therapy&rft.jtitle=Acta%20radiologica%20(1987)&rft.au=Yan,%20Hongjiang&rft.date=2011-07-01&rft.volume=52&rft.issue=6&rft.spage=646&rft.epage=650&rft.pages=646-650&rft.issn=0284-1851&rft.eissn=1600-0455&rft.coden=ACRAE3&rft_id=info:doi/10.1258/ar.2011.100462&rft_dat=%3Cproquest_cross%3E874483565%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c360t-dabeab35c77c79af0f2c47b42346c0f394a3a1fe43744e1906bd4e69f9d8b5703%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=874483565&rft_id=info:pmid/21508201&rft_sage_id=10.1258_ar.2011.100462&rfr_iscdi=true |